Glide’s areas of focus are the development and delivery of solid dose formulations of therapeutics and vaccines delivered using its proprietary solid dose injector, the Glide SDI®.
The Glide SDI® has the potential to improve compliance in patients self-administering long term therapy. It is simple to use and there is no needle disposal problem. Glide’s pipeline of therapeutic products includes octreotide, teriparatide (PTH 1-34) and exenatide, a GLP-1 agonist targeting Type 2 Diabetes.
Solid dose formulation lends itself to the formation of very stable therapeutic or vaccine material and Glide’s vaccine candidates combine ease of administration through use of the Glide SDI®, with antigen stability that may lead to the reduction or even abolition of cold chains during distribution. Glide’s pipeline of vaccine candidates includes an anthrax vaccine (in collaboration with Pfenex, Inc. and supported by NIAID) and an influenza vaccine in collaboration with Cilian AG.